NMPA approves SinoT’s ANDA application for Dapagliflozin and Metformin Hydrochloride Extended-release Tablet
The generic version of "Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets" developed by SinoT was approved by NMPA in September 2024，making it the first generic of XIGDUO XR to be approved in China.
About SinoT：
SinoT is a specialty pharma with focus on the research & development, commercialization and sale of complex generics and 505(b2) products. We dedicated to developing high quality medicines that meet with international standards. We’ll do more than our best to benefit the patients in the future.
Shanghai Head Office
99 Haike Road, Bldg. 3, 1st Flr., Pudong District Shanghai 201210, P.R. China
Manufacturing Site in Jiangsu
No. 163 Zhuhai Road, Haimen Area, Nantong City, Jiangsu Province
